Publication:
Papillophlebitis: Treatment of Vision Loss Due to Subretinal Fluid With Intravitreal Ranibizumab

dc.authorscopusid8540670700
dc.authorscopusid56411901300
dc.authorscopusid6602733678
dc.authorscopusid6603543240
dc.authorwosidYuksel/Aaf-9736-2021
dc.authorwosidKonuk, Şerife Gülhan/Jef-2032-2023
dc.contributor.authorGungor, Inci
dc.contributor.authorKonuk, Gulhan Erciyes
dc.contributor.authorSullu, Yuksel
dc.contributor.authorAriturk, Nursen
dc.contributor.authorIDKonuk, Şeri̇fe Gülhan/0000-0003-4071-5193
dc.date.accessioned2020-06-21T09:37:38Z
dc.date.available2020-06-21T09:37:38Z
dc.date.issued2014
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Gungor, Inci; Konuk, Gulhan Erciyes; Sullu, Yuksel; Ariturk, Nursen] Ondokuz Mayis Univ, Dept Ophthalmol, Fac Med, Samsun, Turkeyen_US
dc.descriptionKonuk, Şeri̇fe Gülhan/0000-0003-4071-5193;en_US
dc.description.abstractThere are no specific treatment protocols for papillophlebitis, which is basically a central retinal vein occlusion (CRVO) occurring in young adults. The present report is that of a 14-year-old girl, who presented with blurred vision in her right eye. Although her visual acuity (VA) was initially 20/20, there were venous engorgements, blurry disc margins, and a substantial collection of subretinal fluid. She was diagnosed with papillophlebitis. When, 2 weeks later, her VA had decreased to 20/200, she was administered intravitreally injected ranibizumab. One week post-injection, her VA had returned to normal (20/20) and the subretinal fluid had diminished markedly. Intravitreal ranibizumab injection appears to be an effective treatment modality for this condition.en_US
dc.description.woscitationindexEmerging Sources Citation Index
dc.identifier.doi10.3109/01658107.2014.954293
dc.identifier.endpage339en_US
dc.identifier.issn0165-8107
dc.identifier.issn1744-506X
dc.identifier.issue6en_US
dc.identifier.pmid27928322
dc.identifier.scopus2-s2.0-84909978381
dc.identifier.scopusqualityQ3
dc.identifier.startpage336en_US
dc.identifier.urihttps://doi.org/10.3109/01658107.2014.954293
dc.identifier.volume38en_US
dc.identifier.wosWOS:000435881400006
dc.language.isoenen_US
dc.publisherTaylor & Francis Asen_US
dc.relation.ispartofNeuro-Ophthalmologyen_US
dc.relation.journalNeuro-Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-VEGFen_US
dc.subjectCentral Retinal Vein Occlusionen_US
dc.subjectMacular Edemaen_US
dc.subjectPapillophlebitisen_US
dc.subjectRanibizumaben_US
dc.titlePapillophlebitis: Treatment of Vision Loss Due to Subretinal Fluid With Intravitreal Ranibizumaben_US
dc.typeArticleen_US
dspace.entity.typePublication

Files